The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
|Videos|March 2, 2019
Dr. Usmani Discusses Management of Early Relapse in Myeloma
Author(s)Saad Z. Usmani, MD, FACP
Saad Z. Usmani, MD, FACP, shares his advice for the management of early relapse in patients with multiple myeloma.
Advertisement
Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, shares his advice for the management of early relapse in patients with multiple myeloma.
According to Usmani, one approach to this situation is not appropriate for all patients. Physicians should consider each regimen that could potentially be used for first relapse to decide which option is best for an individual patient. If there are 2 regimens with similar benefit, convenience for the patient should also be considered.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
The CHMP opinion is backed by phase 3 MonumenTAL-3 data evaluating talquetamab plus daratumumab in relapsed/refractory multiple myeloma.
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Pembrolizumab for Unresectable/Metastatic TMB-H Solid Tumors
2
Experts Tackle Key Questions on CDK4/6 Inhibition Across HR+ Breast Cancer Settings
3
Pembrolizumab Plus Enfortumab Vedotin Earns EC Approval in Resectable MIBC
4
Dr Oberstein on the Rationale for Evaluating the PD-1/IL-15 Fusion Protein SAR445877 in MSS CRC
5